Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Link Found Between Inflammation and Cancer

April 27, 2011
Article

A group of researchers at the Ohio State University Comprehensive Cancer Center (OSUCCC) has discovered that a certain type of RNA, microRNA-155, may provide the link between inflammation and cancer.

A group of researchers at the Ohio State University Comprehensive Cancer Center (OSUCCC) has discovered that a certain type of RNA, microRNA-155, may provide the link between inflammation and cancer. The article describing the study was published online ahead of print in the Proceedings of the National Academy of Science in March (doi: 10.1073/pnas.1101795108).


Carlo M. Croce, MD

Ohio State University
Comprehensive Cancer Center

Many studies have linked chronic inflammation with cancer (ie, inflammatory bowel disease and colorectal cancer), and some estimate that as many as 25% of cancer cases are caused by chronic infection. This study, led by Carlo Croce, showed that inflammation stimulates a rise in levels of micro-RNA-155 (miR-155), and that this, in turn, causes a drop in levels of the proteins involved in DNA repair and results in a higher rate of the spontaneous gene mutations that can lead to cancer.

First author and post-doctoral researcher Esmerina Tili said, “Our study shows that miR-155 is upregulated by inflammatory stimuli and that overexpression of miR-155 increases the spontaneous mutation rate, which can contribute to tumorigenesis. People have suspected for some time that inflammation plays an important role in cancer, and our study presents a molecular mechanism that explains how it happens.”

MicroRNAs are involved in many important cell processes and act by suppressing the amounts of certain proteins; each type of microRNA can affect many different proteins. MiR-155 is known to influence blood-cell maturation, immune responses, and autoimmune disorders, and high levels of the molecule have been directly linked to the development of leukemias as well as breast, lung, and gastric cancers.

In the study, Tili and her colleagues examined the effects of inflammation-promoting substances such as tumor necrosis factor or lipopolysaccharide on miR-155 expression and on the frequency of spontaneous mutations in several breast-cancer cell lines. When the researchers exposed breast-cancer cells to the two inflammatory factors, the levels of miR-155 rose to abnormally high levels, and the mutation rate increased two- to three-fold. To understand why, the investigators focused on WEE1, a kinase that stops the process of cell division to allow damaged DNA to be repaired.

The investigators learned that miR-155 also targets WEE1 and showed that high levels of miR-155 lead to low levels of WEE1. They reasoned that low levels of WEE1 allowed cell division to continue even when DNA damage is present, and that this leads to an increased number of mutations.

“Our study suggests that miR-155, which is associated with inflammation, increases the mutation rate and might be a key player in inflammation-induced cancers generally,” said principal investigator Dr. Carlo M. Croce, professor and chair of molecular virology, immunology and medical genetics, and director of the Human Cancer Genetics program at the OSUCCC – James Cancer Hospital. “This could make miR-155 an important therapeutic target.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

Aarti Chawla;Komal Jhaveri;Patrick Neven, MD, PhD;Monica Lis Casalnuovo;Sung-Bae Kim;Eriko Tokunaga;Philippe Aftimos;Cristina Saura;Joyce A. O’Shaughnessy;Nadia Harbeck, MD, PhD;Lisa A. Carey, MD;Guiseppe Curigliano;Antonio Llombart-Cussac;Elgene Lim, MBBS, FRACP, PhD;María de la Luz García Tinoco;Joohyuk Sohn;Andre Mattar;Qingyuan Zhang;Chiun-Sheng Huang;Chih-Chiang Hung;Jorge Luis Martinez Rodriguez;Manuel Ruiz Borrego
June 16th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

Virginia Kaklamani, MD, DSc;Giorgi Dzagnidze;Nicoleta Zenovia Antone;Anu Thummala;Mikheil Janjalia;Patricia Santi;Carlos Barrios;Mehmet Ali Nahit Sendur;Xiaoling Zhang;Angela Gambioli;Manuel Dominguez;Kathy Puyana Theall;Tomer Wasserman;William J. Gradishar, MD
June 12th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

Antonio Llombart-Cussac;José Manuel Pérez-García;Elena Lopez-Miranda;Rui Rui Zhang;Miguel Sampayo-Cordero;Juliana Carvalho-Santos;Olga Boix;Marta Beltran;Carlos Barrios;Guiseppe Curigliano;Rupert Bartsch;Anne Clair Hardy Bessard;Anna Compagnoni;Kathy Puyana Theall;Thomas Buechele;Tomer Wasserman;Javier Cortés, MD
May 28th 2025
Article

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article
Related Content

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

Aarti Chawla;Komal Jhaveri;Patrick Neven, MD, PhD;Monica Lis Casalnuovo;Sung-Bae Kim;Eriko Tokunaga;Philippe Aftimos;Cristina Saura;Joyce A. O’Shaughnessy;Nadia Harbeck, MD, PhD;Lisa A. Carey, MD;Guiseppe Curigliano;Antonio Llombart-Cussac;Elgene Lim, MBBS, FRACP, PhD;María de la Luz García Tinoco;Joohyuk Sohn;Andre Mattar;Qingyuan Zhang;Chiun-Sheng Huang;Chih-Chiang Hung;Jorge Luis Martinez Rodriguez;Manuel Ruiz Borrego
June 16th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

Virginia Kaklamani, MD, DSc;Giorgi Dzagnidze;Nicoleta Zenovia Antone;Anu Thummala;Mikheil Janjalia;Patricia Santi;Carlos Barrios;Mehmet Ali Nahit Sendur;Xiaoling Zhang;Angela Gambioli;Manuel Dominguez;Kathy Puyana Theall;Tomer Wasserman;William J. Gradishar, MD
June 12th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

Antonio Llombart-Cussac;José Manuel Pérez-García;Elena Lopez-Miranda;Rui Rui Zhang;Miguel Sampayo-Cordero;Juliana Carvalho-Santos;Olga Boix;Marta Beltran;Carlos Barrios;Guiseppe Curigliano;Rupert Bartsch;Anne Clair Hardy Bessard;Anna Compagnoni;Kathy Puyana Theall;Thomas Buechele;Tomer Wasserman;Javier Cortés, MD
May 28th 2025
Article

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.